Last reviewed · How we verify

Sarpogrelate SR 300mg

Seoul National University Hospital · FDA-approved active Small molecule Quality 5/100

Sarpogrelate SR 300mg is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved. Also known as: Anplone SR.

At a glance

Generic nameSarpogrelate SR 300mg
Also known asAnplone SR
SponsorSeoul National University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sarpogrelate SR 300mg

What is Sarpogrelate SR 300mg?

Sarpogrelate SR 300mg is a Small molecule drug developed by Seoul National University Hospital.

Who makes Sarpogrelate SR 300mg?

Sarpogrelate SR 300mg is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

Is Sarpogrelate SR 300mg also known as anything else?

Sarpogrelate SR 300mg is also known as Anplone SR.

What development phase is Sarpogrelate SR 300mg in?

Sarpogrelate SR 300mg is FDA-approved (marketed).

Related